Medicines sold in India with clinical-trial evidence for a new indication

52 of the 884 medicines with a InTxGNN report have a TxGNN-predicted new indication graded at evidence level L1 or L2 (12 at L1, 40 at L2), meaning clinical-trial evidence (randomized trials, Phase 2–3 trials or systematic reviews) was found for it.

The medicines come from the Indian Medicine Dataset, a public GitHub dataset of medicines sold in India (CDSCO approval status is not included in it); the list reflects the drug reports as last updated on 2026-11-06.

Trial evidence for a predicted indication is not proof of efficacy. Every candidate below still requires clinical validation and regulatory review before any clinical use.

Medicines with trial evidence (L1–L2)

Drug	Predicted new indication	Evidence level	Registered trials cited (NCT)
Bendamustine	mantle cell lymphoma	L1	10
Bromfenac	Eye disease	L1	10
Bupropion	attention deficit-hyperactivity disorder	L1	6
Busulfan	myelodysplastic syndrome	L1	10
Clofarabine	myeloid leukemia	L1	10
Dapsone	Pneumocystosis	L1	9
Doxorubicin	Ewing sarcoma	L1	10
Ketorolac	Headache disorder	L1	10
Nepafenac	Eye disease	L1	11
Polidocanol	Esophageal varices with bleeding	L1 (with caveat)	0
Potassium	Hypertensive disorder	L1 (with caveat)	13
Ribavirin	Chronic hepatitis B virus infection	L1 (with caveat)	10
Acetylcysteine	Thrombotic disease	L2	7
Armodafinil	Insomnia	L2	3
Atorvastatin	HIV infectious disease	L2	10
Candesartan	Migraine disorder	L2	4
Cefprozil	urinary tract infection (disease)	L2	0
Citalopram	Obsessive-compulsive disorder	L2	4
Clomipramine	Anxiety disorder	L2	8
Clozapine	Manic bipolar affective disorder	L2	1
Cyclobenzaprine	Myofascial pain syndrome	L2	10
Desoximetasone	Alopecia areata	L2	0
Diazepam	Insomnia (disease)	L2	0
Docetaxel	Ewing sarcoma	L2	8
Eslicarbazepine	Migraine disorder	L2	1
Everolimus	Liposarcoma	L2	1
Fludarabine	Plasma cell myeloma	L2	10
Hydrocortisone	Alopecia areata	L2	1
Ilaprazole	Gastroduodenitis	L2	0
Ketamine	Headache disorder	L2	9
Ledipasvir	Hepatitis B virus infection	L2 (with caveat)	5
Lenalidomide	Myeloid leukemia	L2	10
Levonorgestrel	Acne (disease)	L2	0
Mefenamic Acid	Headache disorder	L2	0
Moclobemide	Agoraphobia	L2	0
Montelukast	Bronchitis	L2	10
Mycophenolate Mofetil	HIV infectious disease	L2 (with caveat)	4
Nortriptyline	Attention deficit-hyperactivity disorder	L2	0
Ofatumumab	Follicular lymphoma	L2	12
Oxaliplatin	Malignant pleural mesothelioma	L2	3
Pimecrolimus	Seborrheic dermatitis	L2	1
Prednisolone	Alopecia areata	L2	0
Propofol	Migraine disorder	L2	3
Regorafenib	Liposarcoma	L2	1
Sucralfate	Duodenogastric reflux	L2	0
Sunitinib	Liposarcoma	L2	2
Tacrolimus	Seborrheic dermatitis	L2	2
Tiapride	Migraine disorder	L2 (with caveat)	0
Tizanidine	Migraine disorder	L2	2
Trazodone	Obsessive-compulsive disorder	L2	0
Trimebutine	Migraine disorder	L2 (with caveat)	0
Vinorelbine	Ewing sarcoma	L2	3

How to read this list

Evidence level follows the site’s criteria: L1 = Multiple Phase 3 RCTs / systematic reviews; L2 = Single RCT or multiple Phase 2 trials. “(with caveat)” means the drug report qualifies the grade; read the note in the report before relying on it.
Predicted new indication is the main prediction shown in each drug report. Indications and contraindications already recorded in the TxGNN knowledge graph are excluded, but some predictions may still overlap an established use; the report explains this where it applies.
Registered trials cited counts the ClinicalTrials.gov (NCT) numbers cited in the drug report. Reports cite a selection of the trials found; 0 means the report cites no registered trial, and its literature evidence section shows the basis for the grade.
For all levels and the full method, see High Evidence (L1-L2), All Drugs and the methodology.

Disclaimer
This report is for academic research reference only and does not constitute medical advice. Always follow your physician's instructions; never adjust medication on your own. Any drug repurposing decision requires full clinical validation and regulatory review.

Reviewed by: 藥提醒科技有限公司 (yao.care)